Development of a novel formulation with hypericin to treat cutaneous leishmaniasis based on photodynamic therapy in in vitro and in vivo studies

An evaluation of the leishmanicidal activity in vitro and in vivo of hypericin, an expanded-spectrum photosensitizer found in Hypericum perforatum, is presented. Hypericin was evaluated against intracellular amastigotes in vitro of Leishmania (Viannia) panamensis. A topical formulation containing 0....

Full description

Saved in:
Bibliographic Details
Published inAntimicrobial agents and chemotherapy Vol. 59; no. 9; pp. 5804 - 5813
Main Authors Montoya, Andrés, Daza, Alejandro, Muñoz, Diana, Ríos, Karina, Taylor, Viviana, Cedeño, David, Vélez, Iván D, Echeverri, Fernando, Robledo, Sara M
Format Journal Article
LanguageEnglish
Published United States American Society for Microbiology 01.09.2015
Subjects
Animals
Anthracenes
Cell Line
Cricetinae
Experimental Therapeutics
Humans
Leishmania - drug effects
Leishmania - pathogenicity
Leishmaniasis, Cutaneous
Leishmaniasis, Cutaneous - drug therapy
Leishmaniasis, Cutaneous - therapy
Perylene
Perylene - analogs & derivatives
Perylene - therapeutic use
Photochemotherapy
Photochemotherapy - methods
Photosensitizing Agents
Photosensitizing Agents - therapeutic use
U937 Cells
Wound Healing - drug effects
Online AccessGet full text

Cover

More Information
Summary:An evaluation of the leishmanicidal activity in vitro and in vivo of hypericin, an expanded-spectrum photosensitizer found in Hypericum perforatum, is presented. Hypericin was evaluated against intracellular amastigotes in vitro of Leishmania (Viannia) panamensis. A topical formulation containing 0.5% hypericin was developed and assayed in vivo in a hamster model of cutaneous leishmaniasis. Results demonstrate that hypericin induces a significant antiamastigote effect in vitro against L. panamensis by decreasing the number of parasites inside infected cells. The topical formulation of 0.5% hypericin allows healing of L. panamensis-induced lesions upon a topical application of 40 mg/day plus visible-light irradiation (5 J/cm(2), 15 min), twice a week for 3 weeks.
Bibliography:ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 23
Citation Montoya A, Daza A, Muñoz D, Ríos K, Taylor V, Cedeño D, Vélez ID, Echeverri F, Robledo SM. 2015. Development of a novel formulation with hypericin to treat cutaneous leishmaniasis based on photodynamic therapy in in vitro and in vivo studies. Antimicrob Agents Chemother 59:5804–5813. doi:10.1128/AAC.00545-15.
Present address: Karina Ríos, Faculty of Health, University of Santander, Cucuta, Colombia; Viviana Taylor, Faculty of Health and Faculty of Basic Sciences, University Santiago de Cali, Valle, Colombia; David Cedeño, Millennium Pain Center, Basic Science, Bloomington, Illinois, USA.
ISSN:0066-4804
1098-6596
DOI:10.1128/AAC.00545-15